Rossari Biotech Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/3s2zsb3rrlgevkrtgv1ygvp5.pdf

Key Takeaways


Performance Drivers & Headwinds

Chari: "We lost some orders because we did not have adequate capacity to service those orders. Otherwise, our quarter would have been more stronger."

Margin Strategy Reset

Chari: "We are now not focusing on margins as percentage at all. I think all of us should be happy that at Rs. 63 crore of EBITDA, we have the highest EBITDA ever. So, we would only focus on our EBITDA as an amount rather than EBITDA as a percentage. We will not be looking at EBITDA as a percentage in the future."

Capacity Expansion


Working Capital & Balance Sheet


Segment-Level Moves & Bets

Chari: "We are prepared to forego business rather than risk our capital. We do not have bad debts in our systems for the past 26 years and we do not want to in the future also."

Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin levelSimilar margins to current 13.1-13.5%At least through end of FY24
Dahej + Unitop CAPEX commissioning20,000 MTPA + 30,000 MTPA projects completedQ3 FY25, phased
FY24 CAPEX spend₹125-130 crore of ₹178 crore totalFY24
Incremental revenue from new CAPEX~₹400 crore in first 1-1.5 years; ~₹600 crore at peak1-4 years from commissioning
ROCE recoveryPeak back to 23-24%~2 years, once new CAPEX reaches substantial utilization
Working capital daysNormalize to 85-90 daysGoing forward, no specific quarter
Textile business improvementPositive outlookFrom January 1, 2024

Key Metrics

MetricQ2 FY24
Consolidated revenue₹483.5 crore, +14% YoY
HPPC segment growth22% YoY, led by Agro, Phenoxy, Institutional Cleaning, Paints, Home & Personal Care
Textile Speciality Chemicals growth5% YoY
AHN segment performanceDown 30% to 35% YoY, due to seasonal variation and reduced feeds business
EBITDA₹63.6 crore, +13% YoY from ₹56.5 crore in Q2 FY23
EBITDA margin13.1%, vs 13.5% in H1 FY24; management prioritizing volume and utilization over margin percentage
PAT₹32.9 crore, +38% YoY from ₹23.9 crore in Q2 FY23
H1 FY24 revenue₹900 crore, vs ₹350 crore in H1 FY20, nearly 3x growth in 3 years
H1 FY24 EBITDA₹121 crore
H1 FY24 PAT₹62 crore
Net debt-to-equity ratio0.05x as of September 2023
Working capital days98 days as of September 2023, vs 79 days in March 2023; targeted 85 to 90 days going forward
ROCE23%, management states it has been constant between 20% to 23% and has not declined
Capacity utilization – Dahej (Rossari)77% to 80%
Capacity utilization – Unitop and TristarNearing 100% in the last quarter
Unitop YoY growthAbout 25%
Tristar YoY growthAbout 18% to 20%
Total announced CAPEX₹178 crore (₹50 crore for Rossari Dahej expansion, ₹128 crore for Unitop Ethoxylation expansion)
CAPEX spent in H1 FY24₹75 crore, across ETP, tank farms, debottlenecking, solar, maintenance, and brand purchases
Full-year FY24 CAPEX estimateAround ₹125-130 crore
Dahej expansion capacity addition20,000 MTPA
Ethoxylation capacity addition (Unitop)30,000 MTPA, augmenting existing 36,000 MTPA
New CAPEX revenue potentialRoughly ₹400 crore in top line in first 1 to 1.5 years; peak asset turn of 4 to 4.5x around the 4-year mark
Bangladesh textile businessDown to one-third of last year's level, due to cautious credit terms